TY - JOUR
T1 - Distinct Effects of Heparin and Interleukin-4 Functionalization on Macrophage Polarization and In Situ Arterial Tissue Regeneration Using Resorbable Supramolecular Vascular Grafts in Rats
AU - Bonito, Valentina
AU - Koch, Suzanne E.
AU - Krebber, Merle M.
AU - Carvajal-Berrio, Daniel A.
AU - Marzi, Julia
AU - Duijvelshoff, Renee
AU - Lurier, Emily B.
AU - Buscone, Serena
AU - Dekker, Sylvia
AU - de Jong, Simone M.J.
AU - Mes, Tristan
AU - Vaessen, Koen R.D.
AU - Brauchle, Eva M.
AU - Bosman, Anton W.
AU - Schenke-Layland, Katja
AU - Verhaar, Marianne C.
AU - Dankers, Patricia Y.W.
AU - Smits, Anthal I.P.M.
AU - Bouten, Carlijn V.C.
N1 - © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2021/11/3
Y1 - 2021/11/3
N2 - Two of the greatest challenges for successful application of small-diameter in situ tissue-engineered vascular grafts are 1) preventing thrombus formation and 2) harnessing the inflammatory response to the graft to guide functional tissue regeneration. This study evaluates the in vivo performance of electrospun resorbable elastomeric vascular grafts, dual-functionalized with anti-thrombogenic heparin (hep) and anti-inflammatory interleukin 4 (IL-4) using a supramolecular approach. The regenerative capacity of IL-4/hep, hep-only, and bare grafts is investigated as interposition graft in the rat abdominal aorta, with follow-up at key timepoints in the healing cascade (1, 3, 7 days, and 3 months). Routine analyses are augmented with Raman microspectroscopy, in order to acquire the local molecular fingerprints of the resorbing scaffold and developing tissue. Thrombosis is found not to be a confounding factor in any of the groups. Hep-only-functionalized grafts resulted in adverse tissue remodeling, with cases of local intimal hyperplasia. This is negated with the addition of IL-4, which promoted M2 macrophage polarization and more mature neotissue formation. This study shows that with bioactive functionalization, the early inflammatory response can be modulated and affect the composition of neotissue. Nevertheless, variability between graft outcomes is observed within each group, warranting further evaluation in light of clinical translation.
AB - Two of the greatest challenges for successful application of small-diameter in situ tissue-engineered vascular grafts are 1) preventing thrombus formation and 2) harnessing the inflammatory response to the graft to guide functional tissue regeneration. This study evaluates the in vivo performance of electrospun resorbable elastomeric vascular grafts, dual-functionalized with anti-thrombogenic heparin (hep) and anti-inflammatory interleukin 4 (IL-4) using a supramolecular approach. The regenerative capacity of IL-4/hep, hep-only, and bare grafts is investigated as interposition graft in the rat abdominal aorta, with follow-up at key timepoints in the healing cascade (1, 3, 7 days, and 3 months). Routine analyses are augmented with Raman microspectroscopy, in order to acquire the local molecular fingerprints of the resorbing scaffold and developing tissue. Thrombosis is found not to be a confounding factor in any of the groups. Hep-only-functionalized grafts resulted in adverse tissue remodeling, with cases of local intimal hyperplasia. This is negated with the addition of IL-4, which promoted M2 macrophage polarization and more mature neotissue formation. This study shows that with bioactive functionalization, the early inflammatory response can be modulated and affect the composition of neotissue. Nevertheless, variability between graft outcomes is observed within each group, warranting further evaluation in light of clinical translation.
KW - biodegradable polymers
KW - cardiovascular
KW - immunomodulatory biomaterials
KW - in situ tissue engineering
KW - Raman microspectroscopy
KW - supramolecular chemistry
KW - tissue-engineered vascular graft (TEVG)
UR - http://www.scopus.com/inward/record.url?scp=85114892906&partnerID=8YFLogxK
U2 - 10.1002/adhm.202101103
DO - 10.1002/adhm.202101103
M3 - Article
C2 - 34523263
SN - 2192-2640
VL - 10
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 21
M1 - e2101103
ER -